| TOCYMA FRESENIUS KABI DEUTSCHLAND GMBH
2011574 14 Feb 2020 | on 27 Jul 2021 | Class 005 Class 005 Pharmaceutical Products Pharmaceutical preparations for human use for the treatment Rheumatoid arthritis (RA), Polyarticular juvenile idiopathic arthritis (pJIA), Systemic juvenile idiopathic arthritis (sJIA), Still's disease, autoimmune diseases, Giant cell arteritis (GCA), CAR T-cell induced cytokine release syndrome, cancer, diabetes, renal failure, cardiovascular diseases, cerebrovascular diseases, respiratory diseases, hematopoietic disorders, bone diseases, systemic lupus erythematosus (SLE), Crohn disease, Castleman's disease, spinal cord injury, and multiple myeloma | | 
